U.S. Markets closed
  • S&P 500

    3,925.43
    +44.06 (+1.14%)
     
  • Dow 30

    31,961.86
    +424.51 (+1.35%)
     
  • Nasdaq

    13,597.97
    +132.77 (+0.99%)
     
  • Russell 2000

    2,284.38
    +53.07 (+2.38%)
     
  • Crude Oil

    63.46
    +1.79 (+2.90%)
     
  • Gold

    1,802.90
    -3.00 (-0.17%)
     
  • Silver

    28.02
    +0.33 (+1.20%)
     
  • EUR/USD

    1.2174
    +0.0019 (+0.1583%)
     
  • 10-Yr Bond

    1.3890
    +0.0270 (+1.98%)
     
  • Vix

    21.34
    -1.77 (-7.66%)
     
  • GBP/USD

    1.4142
    +0.0027 (+0.1937%)
     
  • USD/JPY

    105.8420
    +0.6050 (+0.5749%)
     
  • BTC-USD

    48,415.23
    +990.61 (+2.09%)
     
  • CMC Crypto 200

    968.03
    -46.89 (-4.62%)
     
  • FTSE 100

    6,658.97
    +33.03 (+0.50%)
     
  • Nikkei 225

    29,671.70
    -484.33 (-1.61%)
     

Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson, chairman and chief executive officer, will present at the 23rd Annual Needham Virtual Growth Conference on Wednesday, January 13, 2021, at 4:15 p.m. Eastern Time.

The link to the live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at https://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005763/en/

Contacts

Investors and Media Contact:
Tracy Morris
tracy.morris@veracyte.com
650-380-4413